PCSK9 and familial hypercholesterolemia: In patients with hypercholesterolemia who received background statin and acetyl salicylic acid therapy, platelet function parameters were significantly reduced after 12 months of treatment with the monoclonal antibody (mAb) anti-PCSK9 alirocumab or evolocumab (28).